Papers
1
Total Citations
4
H-Index
1
About
Lin Shen is a prominent urologic oncologist whose research focuses on prostate cancer treatment outcomes and risk stratification, with particular expertise in post-surgical prognostic factors. Drawing from a high-volume center in Southeast China, Shen's landmark study on risk factors for persistent PSA after radical prostatectomy (RP) has garnered significant attention, accumulating 4 citations since its 2024 publication. This work addresses a critical clinical challenge: why some patients fail to achieve undetectable PSA levels following successful RP, which typically reduces PSA below 0.1 ng/mL within 6–8 weeks. By analyzing comprehensive patient data, Shen identified key predictors of biochemical persistence, enabling more personalized postoperative surveillance and adjuvant therapy decisions. The research has direct implications for improving treatment protocols and patient counseling in localized prostate cancer management. Shen's contributions bridge surgical oncology and precision medicine, offering evidence-based frameworks for optimizing outcomes in one of the most common male malignancies. This work positions Shen as an emerging authority in prostate cancer prognostics, with findings that inform clinical practice at major urology centers.
Research Focus
Key Achievements
Top Papers
- 1